Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NYSE | Common Stock
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.
It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine.
In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products.
Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism.
It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; California Institute for Biomedical Research (Calibr), and BigHat Biosciences, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 25, 24 | 2.65 Decreased by -8.93% | 2.56 Increased by +3.52% |
| Apr 26, 24 | 2.31 Decreased by -6.10% | 2.23 Increased by +3.59% |
| Feb 2, 24 | 2.79 Decreased by -22.50% | 2.77 Increased by +0.72% |
| Oct 27, 23 | 2.95 Decreased by -19.40% | 2.86 Increased by +3.15% |
| Jul 27, 23 | 2.91 Decreased by -13.65% | 2.81 Increased by +3.56% |
| Apr 27, 23 | 2.46 Decreased by -24.07% | 2.46 |
| Feb 9, 23 | 3.60 Increased by +8.76% | 3.56 Increased by +1.12% |
| Oct 28, 22 | 3.66 Increased by +9.91% | 3.57 Increased by +2.52% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 13.93 B Decreased by -5.97% | 1.78 B Decreased by -54.98% | Increased by +12.77% Decreased by -52.11% |
| Jun 30, 23 | 13.87 B Decreased by -4.92% | 2.02 B Increased by +119.05% | Increased by +14.60% Increased by +130.39% |
| Mar 31, 23 | 12.22 B Decreased by -9.70% | 239.00 M Decreased by -94.68% | Increased by +1.96% Decreased by -94.11% |
| Dec 31, 22 | 15.12 B Increased by +1.58% | 2.47 B Decreased by -38.85% | Increased by +16.35% Decreased by -39.80% |
| Sep 30, 22 | 14.81 B Increased by +3.28% | 3.95 B Increased by +24.22% | Increased by +26.66% Increased by +20.28% |
| Jun 30, 22 | 14.58 B Increased by +4.47% | 924.00 M Increased by +20.63% | Increased by +6.34% Increased by +15.47% |
| Mar 31, 22 | 13.54 B Increased by +4.06% | 4.49 B Increased by +26.30% | Increased by +33.17% Increased by +21.38% |
| Dec 31, 21 | 14.89 B Increased by +7.42% | 4.04 B Increased by +11.13 K% | Increased by +27.17% Increased by +10.36 K% |